← Research ProtocolsLiraglutide
STUDIED EXPOSURE MAP / 2015
Liraglutide
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / RANDOMIZED CONTROLLEDNEW ENGLAND JOURNAL OF MEDICINESTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
3.0 mg
SC · once daily · target trial dose
Context: This is a defined clinical-trial target dose in a specific population. It is shown for study context only.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / NEW ENGLAND JOURNAL OF MEDICINE
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2015
01 / DESIGN56-week · double-blind · randomized · placebo-controlled
02 / POPULATION / MODEL3,731 adults with obesity or overweight plus qualifying comorbidity, without type 2 diabetes
03 / ROUTESubcutaneous · once daily
04 / TIMEFRAME56 weeks
05 / PRIMARY QUESTIONBody-weight change and categorical weight-loss outcomes
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Broader research index. This entity is not presented here as an ENHANCED catalogue compound.
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.